XML 40 R11.htm IDEA: XBRL DOCUMENT
v3.8.0.1

Goodwill and Other Intangible Assets | 6 Months Ended
--- | ---
Dec. 31, 2017
Goodwill and Intangible Assets Disclosure [Abstract] |
Goodwill and Other Intangible Assets | 5. Goodwill and Other Intangible Assets Goodwill The following table summarizes the changes in the carrying amount of goodwill by segment and in total:
(in millions) | Pharmaceutical |  | Medical |  | Total
Balance at June 30, 2017 | $ | 2,939 |  |  | $ | 4,282 |  |  | $ | 7,221 |
Goodwill acquired, net of purchase price adjustments | 1 |  |  | 3,187 |  |  | 3,188 |
Foreign currency translation adjustments and other | 14 |  |  | 9 |  |  | 23 |
Reclassified to assets held for sale | (333 | ) |  | (54 | ) |  | (387 | )
Balance at December 31, 2017 | $ | 2,621 |  |  | $ | 7,424 |  |  | $ | 10,045 |
The increase in the Medical segment goodwill is primarily due to the Patient Recovery Business acquisition. Goodwill recognized in connection with the Patient Recovery Business acquisition primarily represents the expected benefits from certain synergies of integrating the business, the existing workforce of the acquired entity, and the expected growth from new customers. During the three months ended December 31, 2017, goodwill of $387 million was reclassified to assets held for sale in connection with the sale of our China distribution business, discussed further in Note 4. Other Intangible Assets The following tables summarize other intangible assets by class at:
| December 31, 2017
(in millions) | Gross Intangible |  | Accumulated Amortization |  | Net Intangible |  | Weighted- Average Remaining Amortization Period (Years)
Indefinite-life intangibles: |  |  |  |  |  |  |
IPR&D, trademarks and other | $ | 62 |  |  | $ | — |  |  | $ | 62 |  |  | N/A
Total indefinite-life intangibles | 62 |  |  | — |  |  | 62 |  |  | N/A
Definite-life intangibles: |  |  |  |  |  |  |
Customer relationships | 3,614 |  |  | 1,074 |  |  | 2,540 |  |  | 13
Trademarks, trade names and patents | 686 |  |  | 224 |  |  | 462 |  |  | 14
Developed technology and other | 1,648 |  |  | 391 |  |  | 1,257 |  |  | 12
Total definite-life intangibles | 5,948 |  |  | 1,689 |  |  | 4,259 |  |  | 13
Total other intangible assets | $ | 6,010 |  |  | $ | 1,689 |  |  | $ | 4,321 |  |  | N/A
| June 30, 2017
(in millions) | Gross Intangible |  | Accumulated Amortization |  | Net Intangible
Indefinite-life intangibles: |  |  |  |  |
IPR&D, trademarks and other | $ | 61 |  |  | $ | — |  |  | $ | 61 |
Total indefinite-life intangibles | 61 |  |  | — |  |  | 61 |
Definite-life intangibles: |  |  |  |  |
Customer relationships | 1,966 |  |  | 967 |  |  | 999 |
Trademarks, trade names and patents | 509 |  |  | 195 |  |  | 314 |
Developed technology and other | 916 |  |  | 304 |  |  | 612 |
Total definite-life intangibles | 3,391 |  |  | 1,466 |  |  | 1,925 |
Total other intangible assets | $ | 3,452 |  |  | $ | 1,466 |  |  | $ | 1,986 |
The increase in definite-life intangibles is primarily due to the Patient Recovery Business acquisition. Total amortization of intangible assets was $152 million and $95 million for the three months ended December 31, 2017 and 2016, respectively, and $287 million and $196 million for the six months ended December 31, 2017 and 2016, respectively. For acquisitions closed on or before December 31, 2017, estimated annual amortization of intangible assets for the remainder of fiscal 2018 through 2022 is as follows: $289 million, $553 million, $522 million, $450 million and $417 million. During the three months ended December 31, 2017, other intangible assets of $61 million were transferred to assets held for sale in connection with the sale of our China distribution business, discussed further in Note 4.

X
- References No definition available. + Details
Name: | us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for the aggregate amount of goodwill and a description of intangible assets, which may include (a) for amortizable intangible assets (also referred to as finite-lived intangible assets), the carrying amount, the amount of any significant residual value, and the weighted-average amortization period, (b) for intangible assets not subject to amortization (also referred to as indefinite-lived intangible assets), the carrying amount, and (c) the amount of research and development assets acquired and written off in the period, including the line item in the income statement in which the amounts written off are aggregated, if not readily apparent from the income statement. Also discloses (a) for amortizable intangibles assets in total and by major class, the gross carrying amount and accumulated amortization, the total amortization expense for the period, and the estimated aggregate amortization expense for each of the five succeeding fiscal years, (b) for intangible assets not subject to amortization the carrying amount in total and by major class, and (c) for goodwill, in total and for each reportable segment, the changes in the carrying amount of goodwill during the period (including the aggregate amount of goodwill acquired, the aggregate amount of impairment losses recognized, and the amount of goodwill included in the gain (loss) on disposal of a reporting unit). If any part of goodwill has not been allocated to a reportable segment, discloses the unallocated amount and the reasons for not allocating. For each impairment loss recognized related to an intangible asset (excluding goodwill), discloses: (a) a description of the impaired intangible asset and the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method for determining fair value, (c) the caption in the income statement or the statement of activities in which the impairment loss is aggregated, and (d) the segment in which the impaired intangible asset is reported. For each goodwill impairment loss recognized, discloses: (a) a description of the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method of determining the fair value of the associated reporting unit, and (c) if a recognized impairment loss is an estimate not finalized and the reasons why the estimate is not final. May also disclose the nature and amount of any significant adjustments made to a previous estimate of an impairment loss. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -URI http://asc.fasb.org/topic&trid=2144416 + Details
Name: | us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration